164 related articles for article (PubMed ID: 28361959)
21. A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer.
Lin SF; Lin JD; Hsueh C; Chou TC; Wong RJ
PLoS One; 2017; 12(2):e0172315. PubMed ID: 28207834
[TBL] [Abstract][Full Text] [Related]
22. Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma.
Höring E; Montraveta A; Heine S; Kleih M; Schaaf L; Vöhringer MC; Esteve-Arenys A; Roué G; Colomer D; Campo E; Ott G; Aulitzky WE; van der Kuip H
Br J Haematol; 2017 May; 177(4):557-561. PubMed ID: 28295185
[TBL] [Abstract][Full Text] [Related]
23. Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors.
Floros KV; Jacob S; Kurupi R; Fairchild CK; Hu B; Puchalapalli M; E Koblinski J; Dozmorov MG; Boikos SA; Scaltriti M; Faber AC
Cell Death Dis; 2021 Feb; 12(2):179. PubMed ID: 33589591
[TBL] [Abstract][Full Text] [Related]
24. Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression.
Hossain DMS; Javaid S; Cai M; Zhang C; Sawant A; Hinton M; Sathe M; Grein J; Blumenschein W; Pinheiro EM; Chackerian A
J Clin Invest; 2018 Feb; 128(2):644-654. PubMed ID: 29337311
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of CD73 using folate targeted nanoparticles carrying anti-CD73 siRNA potentiates anticancer efficacy of Dinaciclib.
Hallaj S; Heydarzadeh Asl S; Alian F; Farshid S; Eshaghi FS; Namdar A; Atyabi F; Masjedi A; Hallaj T; Ghorbani A; Ghalamfarsa G; Sojoodi M; Jadidi-Niaragh F
Life Sci; 2020 Oct; 259():118150. PubMed ID: 32726663
[TBL] [Abstract][Full Text] [Related]
26. Study of the mechanism by which dinaciclib induces apoptosis and cell cycle arrest of lymphoma Raji cells through a CDK1-involved pathway.
Zhao H; Li S; Wang G; Zhao W; Zhang D; Wang F; Li W; Sun L
Cancer Med; 2019 Aug; 8(9):4348-4358. PubMed ID: 31207099
[TBL] [Abstract][Full Text] [Related]
27. Bcl-x
Rello-Varona S; Fuentes-Guirado M; López-Alemany R; Contreras-Pérez A; Mulet-Margalef N; García-Monclús S; Tirado OM; García Del Muro X
Sci Rep; 2019 Mar; 9(1):3816. PubMed ID: 30846724
[TBL] [Abstract][Full Text] [Related]
28. Codelivery of HIF-1α siRNA and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression.
Izadi S; Moslehi A; Kheiry H; Karoon Kiani F; Ahmadi A; Masjedi A; Ghani S; Rafiee B; Karpisheh V; Hajizadeh F; Atyabi F; Assali A; Mirzazadeh Tekie FS; Namdar A; Ghalamfarsa G; Sojoodi M; Jadidi-Niaragh F
Pharm Res; 2020 Sep; 37(10):196. PubMed ID: 32944844
[TBL] [Abstract][Full Text] [Related]
29. A novel kinase inhibitor, LZT-106, downregulates Mcl-1 and sensitizes colorectal cancer cells to BH3 mimetic ABT-199 by targeting CDK9 and GSK-3β signaling.
Yu Z; Du J; Zhao Y; Gao Y; Li Y; Zhao K; Lu N
Cancer Lett; 2021 Feb; 498():31-41. PubMed ID: 33129955
[TBL] [Abstract][Full Text] [Related]
30. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models.
Feldmann G; Mishra A; Bisht S; Karikari C; Garrido-Laguna I; Rasheed Z; Ottenhof NA; Dadon T; Alvarez H; Fendrich V; Rajeshkumar NV; Matsui W; Brossart P; Hidalgo M; Bannerji R; Maitra A; Nelkin BD
Cancer Biol Ther; 2011 Oct; 12(7):598-609. PubMed ID: 21768779
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression.
Xu J; Huang F; Yao Z; Jia C; Xiong Z; Liang H; Lin N; Deng M
Cell Commun Signal; 2019 Jul; 17(1):85. PubMed ID: 31349793
[TBL] [Abstract][Full Text] [Related]
32. Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics.
Choudhary GS; Tat TT; Misra S; Hill BT; Smith MR; Almasan A; Mazumder S
Oncotarget; 2015 Jul; 6(19):16912-25. PubMed ID: 26219338
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of stearoyl-coA desaturase selectively eliminates tumorigenic Nanog-positive cells: improving the safety of iPS cell transplantation to myocardium.
Zhang L; Pan Y; Qin G; Chen L; Chatterjee TK; Weintraub NL; Tang Y
Cell Cycle; 2014; 13(5):762-71. PubMed ID: 24394703
[TBL] [Abstract][Full Text] [Related]
34. c-MYC independent nuclear reprogramming favors cardiogenic potential of induced pluripotent stem cells.
Martinez-Fernandez A; Nelson TJ; Ikeda Y; Terzic A
J Cardiovasc Transl Res; 2010 Feb; 3(1):13-23. PubMed ID: 20221419
[TBL] [Abstract][Full Text] [Related]
35. Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia.
Chen Y; Germano S; Clements C; Samuel J; Shelmani G; Jayne S; Dyer MJ; Macip S
Br J Haematol; 2016 Nov; 175(4):641-651. PubMed ID: 27469405
[TBL] [Abstract][Full Text] [Related]
36. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.
Goodwin CM; Rossanese OW; Olejniczak ET; Fesik SW
Cell Death Differ; 2015 Dec; 22(12):2098-106. PubMed ID: 26045046
[TBL] [Abstract][Full Text] [Related]
37. TRPV-1-mediated elimination of residual iPS cells in bioengineered cardiac cell sheet tissues.
Matsuura K; Seta H; Haraguchi Y; Alsayegh K; Sekine H; Shimizu T; Hagiwara N; Yamazaki K; Okano T
Sci Rep; 2016 Feb; 6():21747. PubMed ID: 26888607
[TBL] [Abstract][Full Text] [Related]
38. Induced Pluripotent Stem Cell Elimination in a Cell Sheet by Methionine-Free and 42°C Condition for Tumor Prevention.
Matsuura K; Ito K; Shiraki N; Kume S; Hagiwara N; Shimizu T
Tissue Eng Part C Methods; 2018 Oct; 24(10):605-615. PubMed ID: 30234460
[TBL] [Abstract][Full Text] [Related]
39. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
[TBL] [Abstract][Full Text] [Related]
40. Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with
Nelson LJ; Castro KE; Xu B; Li J; Dinh NB; Thompson JM; Woytash J; Kipp KR; Razorenova OV
Cell Cycle; 2022 May; 21(10):1103-1119. PubMed ID: 35240916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
